Clinical Trial Update: Phase 2 Study of AMG 337 in MET Amplified Gastric/Esophageal Adenocarcinoma or Other Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of AMG 337 in MET-amplified gastric and esophageal adenocarcinoma and other solid tumors has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Adenocarcinoma
• Gastric Adenocarcinoma

Drugs mentioned

• AMG 337

Snippet

Sponsor: Amgen | Conditions: Stomach Neoplasms | Phase 2 | Status: TERMINATED